ClinicalTrials.gg
CompletedNCT03384862Updated Feb 16, 2021

Nutrition, Arsenic and Cognitive Function in Children

An interventional study of Vitamin B12 and Placebo in Arsenic Exposure, sponsored by Columbia University. Completed at 1 site in Bangladesh. Open to participants aged 8 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Columbia University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
8 Years to 10 Years
Sex
All
01

Study summary

The main goals of this study are to evaluate whether supplementation with folate and vitamin B12 to 8 to 10 year old children, in conjunction with reduction in arsenic exposure, can increase arsenic methylation and lower blood arsenic and blood monomethyl arsenic (as previously observed in adults). The investigators will also explore whether folate and B12 can mitigate arsenic-related decrements in cognitive abilities.

Read the detailed description

While reducing arsenic (As) exposure in Bangladesh and the U.S. must continue to be a top priority, this has proven difficult. After decades of efforts to reduce exposure, 42 million people in Bangladesh remain exposed to As above 10 µg/L, the WHO guideline for As in drinking water. Risk for arsenic-related health outcomes lingers for decades after exposure has been reduced. Innovative strategies to lower arsenic exposure and and reduce its potential adverse health effects of As are needed.

02

Conditions studied

  • Arsenic Exposure

Keywords

  • Arsenic exposure
03

In context

Lead sponsor

Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.

Of its 180 completed or terminated interventional studies of FDA-regulated products, 148 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age-eligible children of parents enrolled in the Health Effects of Arsenic Longitudinal Study cohort

Exclusion criteria

Exclusion Criteria:

  • siblings
  • twins
  • children who are not attending school
  • children with known physical disability or known chronic illness
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Nutritional Intervention Arm

    5 μg vitamin B12 plus 400 μg folic acid

    Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

  • Placebo comparator
    Control Arm

    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementVitamin B12

    5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.

  • Dietary supplementPlacebo

    Placebo pills, with same appearance as intervention pills.

  • Dietary supplementFolic Acid

    400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.

06

What researchers measure

Primary outcomes

  1. Change in arsenic methylation

    Change in arsenic methylation patterns in blood and urine. The ability to methylate arsenic influences an individual's ability to excrete it in urine.

    Time frame: Up to 12 Weeks

  2. Change in in blood arsenic

    Change in arsenic level in blood is to be measured in mg/L. This is an indicator of the body burden of arsenic and arsenic excretion

    Time frame: Up to 12 Weeks

  3. Change in blood monomethyl arsenic

    Change in monomethyl arsenic level in blood is to be measured in units of ug/L. This is an indicator of the body burden of arsenic and arsenic methylation capacity.

    Time frame: Up to 12 Weeks

Other outcomes

  1. Change in WASI-II cognitive function test score

    An improvement in scores on a test of cognitive function after receiving dietary supplements represent potential partial mitigation of arsenic- and nutrition-related cognitive decrements. Wechsler Abbreviated Scale of Intelligence (WASI-II) is a screen of verbal, non-verbal, and general cognitive ability. Higher score indicates higher cognitive function. Scores on the WASI-II can range from below 70 (demonstrating cognitive deficiency) to above 200 (demonstrating incredible genius) - typical "normal" or "average" scores are between 90-100. Higher values indicate a better score in terms of cognitive outcome while lower values indicate a poorer score. An improvement on WASI-II test scores for these participants would be demonstrated in a higher score on this test after receiving the intervention.

    Time frame: Up to 12 Weeks

07

Study locations

1 site
  • Columbia University Bangladesh
    Dhaka, Bangladesh
08

References and documents

Publications

  • Bae S, Kamynina E, Guetterman HM, Farinola AF, Caudill MA, Berry RJ, Cassano PA, Stover PJ. Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults. Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD012649. doi: 10.1002/14651858.CD012649.pub2. PubMed 34661903 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in May 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Dec 28, 2017
StartActual
Jan 27, 2018
Primary completionActual
May 9, 2019
CompletionActual
May 9, 2019
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03384862
Responsible party
Mary Gamble (Associate Professor of Environmental Health Sciences, Columbia University) — Principal investigator
First posted
Dec 28, 2017
Start date
Jan 27, 2018
Primary completion
May 9, 2019
Completion
May 9, 2019
Last update
Feb 16, 2021

Study contacts

Mary V Gamble, PhD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vitamin B 12 · Folic Acid

Start the discussion